# EDGAR Filing Document

**Accession Number:** 0001802528
**File Stem:** 0001104659-25-090015
**Filing Date:** 2025-9
**Character Count:** 23968
**Document Hash:** fce85cc854c0d6bbe2fa96eada912f38
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-090015.hdr.sgml**: 20250915

**ACCESSION NUMBER**: 0001104659-25-090015

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250915

**DATE AS OF CHANGE**: 20250915

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dianthus Therapeutics, Inc. /DE/
- **CENTRAL INDEX KEY:** 0001690585
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90538
- **FILM NUMBER:** 251314498

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 929-999-4055

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Magenta Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20161121
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fairmount Funds Management LLC
- **CENTRAL INDEX KEY:** 0001802528

**ORGANIZATION NAME:**
- **EIN:** 364841215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE
- **STREET 2:** SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 267-262-5300

**MAIL ADDRESS:**
- **STREET 1:** 200 BARR HARBOR DRIVE
- **STREET 2:** SUITE 400
- **CITY:** WEST CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

## Exhibit 99.1

**EXHIBIT 99.1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Dianthus Therapeutics, Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filing.

The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13D and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

Date: September 15, 2025

---

| | | |
|:---|:---|:---|
| **FAIRMOUNT FUNDS MANAGEMENT LLC** | **FAIRMOUNT FUNDS MANAGEMENT LLC** | **FAIRMOUNT FUNDS MANAGEMENT LLC** |
| By: | /s/ Peter Harwin | /s/ Tomas Kiselak |
|  | Peter Harwin | Tomas Kiselak |
|  | Managing Member | Managing Member |
| **FAIRMOUNT HEALTHCARE FUND II L.P.** | **FAIRMOUNT HEALTHCARE FUND II L.P.** | **FAIRMOUNT HEALTHCARE FUND II L.P.** |
| By: | /s/ Peter Harwin | /s/ Tomas Kiselak |
|  | Peter Harwin | Tomas Kiselak |
|  | Managing Member | Managing Member |

---

---

| | |
|:---|:---|
| **FAIRMOUNT SPV III, LLC** | **FAIRMOUNT SPV III, LLC** |
| By: Fairmount Funds Management LLC, its Class A Member | By: Fairmount Funds Management LLC, its Class A Member |
| /s/ Peter Harwin | /s/ Tomas Kiselak |
| Peter Harwin | Tomas Kiselak |
| Managing Member | Managing Member |

---

---

| |
|:---|
| /s/ Peter Harwin |
| Peter Harwin |
| /s/ Tomas Kiselak |
| Tomas Kiselak |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Dianthus Therapeutics, Inc. /DE/**

*(Name of Issuer)*

**Common Stock, $0.001 par value**

*(Title of Class of Securities)*

**252828108**

*(CUSIP Number)*

**Ms. Erin O'Connor**<br>Fairmount Funds Management LLC<br>200 Barr Harbor Drive, Suite 400<br>West Conshohocken PA 19428<br>(267) 262-5300

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **252828108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fairmount Funds Management LLC** | Name of reporting person<br>**Fairmount Funds Management LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4052052.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4052052.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4052052.00** | Aggregate amount beneficially owned by each reporting person<br>**4052052.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** The securities include (i) 3,307,191 shares of common stock, $0.001 par value ("Common Stock"), and (ii) pre-funded warrants to purchase up to 744,861 shares of Common Stock (the "Pre-Funded Warrants"), the exercise of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock. The securities exclude shares of Common Stock issuable upon exercise of the Pre-Funded Warrants in excess of the beneficial ownership limitation.

Row 13 is based on 40,561,085 shares of Common Stock outstanding as of September 11, 2025, consisting of (i) 32,188,345 shares of Common Stock outstanding as of August 6, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) a total of 7,627,879 shares of Common Stock issued in the Company's underwritten public offering on September 11, 2025, as reported in the Company's Current Report on Form 8-K filed on September 11, 2025, and (iii) the 744,861 shares of Common Stock underlying the Pre-Funded Warrants owned by the Reporting Persons, subject to the beneficial ownership limitation.

| **CUSIP No.** | **252828108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fairmount Healthcare Fund II L.P.** | Name of reporting person<br>**Fairmount Healthcare Fund II L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4052052.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4052052.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4052052.00** | Aggregate amount beneficially owned by each reporting person<br>**4052052.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The securities include (i) 3,307,191 shares of Common Stock, and (ii) 744,861 shares of Pre-Funded Warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock. The securities exclude shares of Common Stock issuable upon exercise of the Pre-Funded Warrants in excess of the beneficial ownership limitation.

Row 13 is based on 40,561,085 shares of Common Stock outstanding as of September 11, 2025, consisting of (i) 32,188,345 shares of Common Stock outstanding as of August 6, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) a total of 7,627,879 shares of Common Stock issued in the Company's underwritten public offering on September 11, 2025, as reported in the Company's Current Report on Form 8-K filed on September 11, 2025, and (iii) the 744,861 shares of Common Stock underlying the Pre-Funded Warrants owned by the Reporting Persons, subject to the beneficial ownership limitation.

| **CUSIP No.** | **252828108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fairmount SPV III, LLC** | Name of reporting person<br>**Fairmount SPV III, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **252828108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Peter Evan Harwin** | Name of reporting person<br>**Peter Evan Harwin** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4052052.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4052052.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4052052.00** | Aggregate amount beneficially owned by each reporting person<br>**4052052.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The securities include (i) 3,307,191 shares of Common Stock, and (ii) 744,861 shares of Pre-Funded Warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock. The securities exclude shares of Common Stock issuable upon exercise of the Pre-Funded Warrants in excess of the beneficial ownership limitation.

Row 13 is based on 40,561,085 shares of Common Stock outstanding as of September 11, 2025, consisting of (i) 32,188,345 shares of Common Stock outstanding as of August 6, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) a total of 7,627,879 shares of Common Stock issued in the Company's underwritten public offering on September 11, 2025, as reported in the Company's Current Report on Form 8-K filed on September 11, 2025, and (iii) the 744,861 shares of Common Stock underlying the Pre-Funded Warrants owned by the Reporting Persons, subject to the beneficial ownership limitation.

| **CUSIP No.** | **252828108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Tomas Kiselak** | Name of reporting person<br>**Tomas Kiselak** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2B** | Citizenship or place of organization<br>**2B** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4052052.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4052052.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4052052.00** | Aggregate amount beneficially owned by each reporting person<br>**4052052.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The securities include (i) 3,307,191 shares of Common Stock and (ii) 744,861 shares of Pre-Funded Warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock. The securities exclude shares of Common Stock issuable upon exercise of the Pre-Funded Warrants in excess of the beneficial ownership limitation.

Row 13 is based on 40,561,085 shares of Common Stock outstanding as of September 11, 2025, consisting of (i) 32,188,345 shares of Common Stock outstanding as of August 6, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) a total of 7,627,879 shares of Common Stock issued in the Company's underwritten public offering on September 11, 2025, as reported in the Company's Current Report on Form 8-K filed on September 11, 2025, and (iii) the 744,861 shares of Common Stock underlying the Pre-Funded Warrants owned by the Reporting Persons, subject to the beneficial ownership limitation.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.001 par value

**(b) Name of Issuer:**
Dianthus Therapeutics, Inc. /DE/

**(c) Address of Issuer's Principal Executive Offices:**
7 Times Square, 43rd Floor, New York, NY, 10036

This Amendment No. 3 amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission on September 21, 2023, Amendment No. 1 filed on January 24, 2024, and Amendment No. 2 filed on April 1, 2024 (as amended, the "Statement" or the "Schedule 13D") by the Reporting Persons with respect to the common stock, $0.001 par value ("Common Stock"), of Dianthus Therapeutics, Inc. (the "Company"). Unless otherwise defined herein, capitalized terms used in this Amendment No. 3 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. The address of the principal executive offices of the Company is 7 Times Square, 43rd Floor, New York, NY 10036.

**Item 4. Purpose of Transaction**

Item 4 of the Statement is hereby amended and supplemented as follows:

Fund II purchased the shares of Common Stock referenced in Item 3 for investment purposes.

On March 4, 2025, Mr. Kiselak resigned from the Board of Directors of the Company. Mr. Kiselak's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. As a result of his resignation, Mr. Kiselak no longer may be deemed to have influence over the corporate activities of the Company, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

The Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the board of directors of the Company with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Company or other persons.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information in rows 11 and 13 of each of the cover pages of this Amendment No. 3 is incorporated by reference herein.

The percentages used in this Schedule 13D are calculated based upon 40,561,085 shares of Common Stock outstanding as of September 11, 2025, consisting of (i) 32,188,345 shares of Common Stock outstanding as of August 6, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) a total of 7,627,879 shares of Common Stock issued in the Company's underwritten public offering on September 11, 2025, as reported in the Company's Current Report on Form 8-K filed on September 11, 2025, and (iii) the 744,861 shares of Common Stock underlying the Pre-Funded Warrants owned by the Reporting Persons, subject to the beneficial ownership limitation.

**(b)**
The information in rows 7 through 10 of each of the cover pages of this Amendment No. 3 is incorporated by reference herein.

The Reporting Persons' securities consist of (a) 3,307,191 shares of Common Stock, and (b) Pre-Funded Warrants to purchase up to 744,861 shares of Common Stock, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Common Stock. The securities exclude shares of Common Stock issuable upon exercise of the Pre-Funded Warrants in excess of the beneficial ownership limitation.

**(c)**
On September 11, 2025, Fund II purchased a total of 600,000 shares of Common Stock from the Company at a price of $33.00 per share, for an aggregate of $19,800,000 in an underwritten public offering.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fairmount Funds Management LLC

**Signature:** /s/ Peter Harwin

**Name/Title:** Peter Harwin, Managing Member

**Date:** 09/15/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fairmount Healthcare Fund II L.P.

**Signature:** /s/ Peter Harwin

**Name/Title:** Peter Harwin, Managing Member

**Date:** 09/15/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fairmount SPV III, LLC

**Signature:** By: Fairmount Funds Management LLC, its Class A Member, /s/ Peter Harwin

**Name/Title:** Peter Harwin, Managing Member

**Date:** 09/15/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Peter Evan Harwin

**Signature:** /s/ Peter Harwin

**Name/Title:** Peter Harwin

**Date:** 09/15/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Tomas Kiselak

**Signature:** /s/ Tomas Kiselak

**Name/Title:** Tomas Kiselak

**Date:** 09/15/2025